OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
South San Francisco
Brian Kelley is vice president, bioprocess development at Genentech, Inc.
Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.